Decapeptyl Adverse Reactions

Frequently (≥ 2%) reported adverse events during treatment with DECAPEPTYL 0.1 mg/1 ml in clinical trials, either before or during co-administration with gonadotrophins, are listed in the table as follows. The most frequent adverse events are headache (27%), vaginal bleeding/spotting (24%), abdominal pain (15%), injection site inflammation (12%) and nausea (10%).
Mild to severe hot flushes and hyperhidrosis may occur which do not usually require discontinuation of therapy.
At the beginning of treatment with DECAPEPTYL 0.1 mg/1 ml, the combination with gonadotrophins may result in ovarian hyperstimulation syndrome. Ovarian enlargement, dyspnoea, pelvic and/or abdominal pain may be observed (refer to Precautions). Genital haemorrhage including menorrhagia and metrorrhagia may occur at the beginning of treatment with DECAPEPTYL 0.1 mg/1 ml.
Ovarian cysts have been reported to occur commonly (1%) during the initial phase of treatment with DECAPEPTYL.
During treatment with triptorelin some adverse reactions showed a general pattern of hypo-oestrogenic events related to pituitary-ovarian blockade such as sleep disorder, headache, mood altered, vulvovaginal dryness, dyspareunia and libido decreased.
Breast pain, muscle spasms, arthralgia, weight increased, nausea, abdominal pain, abdominal discomfort, asthenia and episodes of blurred vision and visual disturbances may occur during treatment with DECAPEPTYL 0.1 mg/1 ml.
Single cases of allergic reactions, localized or generalized, have been reported after injection of DECAPEPTYL. (See table.)

Click on icon to see table/diagram/image